Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide by Goli, Veeraindar et al.
RESEARCH Open Access
Effects of concurrent intravenous morphine
sulfate and naltrexone hydrochloride on end-tidal
carbon dioxide
Veeraindar Goli
1,2,5*, Lynn R Webster
3, Michael J Lamson
1, Jody M Cleveland
1, Kenneth W Sommerville
1,2 and
Eric Carter
4
Abstract
Background: Respiratory depression, a potentially fatal side-effect of opioid-overdose, may be reversed by timely
administration of an opioid antagonist, such as naloxone or naltrexone. Tampering with a formulation of morphine
sulfate and sequestered naltrexone hydrochloride extended release capsules (MS-sNT) releases both the opioid
morphine and the antagonist naltrexone. A study in recreational opioid-users indicated that morphine and
naltrexone injected in the 25:1 ratio (duplicating the ratio of the formulation) found MS-sNT reduced morphine-
induced euphoric effects vs intravenous (IV) morphine alone. In the same study, the effects of morphine +
naltrexone on end-tidal carbon dioxide (EtCO2), a measure of respiratory-depression, were evaluated and these
data are reported here.
Methods: Single-center, placebo-controlled, double-blind crossover study. Non-dependent male opioid users were
randomized to receive single IV doses of placebo, 30 mg morphine alone, and 30 mg morphine + 1.2 mg
naltrexone. EtCO2 was measured by noninvasive capnography.
Results: Significant differences in EtCO2 least-squares means across all treatments for maximal effect (Emax) and
area under the effect curve (AUE0-2, AUE0-8, AUE0-24) were detected (all p ≤ 0.0011). EtCO2 Emax values for morphine
+ naltrexone were significantly reduced vs morphine alone (42.9 mm Hg vs 47.1 mm Hg, p < 0.0001) and were
not significantly different vs placebo (41.9 mm Hg). Median time to reach maximal effect (TEmax) was delayed for
morphine + naltrexone vs morphine alone (5.0 h vs 1.0 h).
Conclusions: Results provide preliminary evidence that the naltrexone:morphine ratio within MS-sNT is sufficient to
significantly reduce EtCO2 when administered intravenously to non-dependent male recreational opioid-users.
Further studies with multiple measures of respiratory-function are warranted to determine if risk of respiratory
depression is also reduced by naltrexone in the tampered formulation.
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Background
In the United States in 2007, more than one-third (36%)
of all poisoning deaths involved opioid analgesics (drugs
usually prescribed to relieve pain) [1]. Since 1999, poi-
soning deaths in the United States involving opioid
analgesics have more than tripled [1,2]; deaths from
opioid analgesics have surpassed those from heroin and
cocaine [3,4].
Although prescription opioids may be formulated for
oral use, they are often taken intravenously or intrana-
sally when abused [5,6]. As tolerance to opioid psychoac-
tive effects increases with use over time, the user often
progresses from the oral route to the intranasal or intra-
venous (IV) route to attain greater opioid effects and
more rapid onset of action [5,7-10].
Respiratory depression is the leading cause of death
following opioid overdose [11]. Opioids interact with
μ-opioid receptors, reducing the central nervous system
responsiveness to hypercapnia and hypoxia, and the
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[11-14]. Respiratory depression involves inadequate
response to hypercapnia or hypoxia, resulting in a
decrease in respiratory rate and/or decrease in minute
ventilation below normal [15,16]. Respiratory depression
can be defined as a deviation of respiratory rate, pulse
oximetry value, or carbon dioxide tension from an arbi-
trary threshold [17,18]. Opioid-induced respiratory
depression can occur within minutes of IV injection and
typically can result in death in < 1 to 3 hours following
opioid exposure [7,19,20].
Respiratory depression can be reversed by timely
administration of an opioid antagonist [21]. However, as
respiratory depression can develop within minutes, the
interval for successful intervention can be short [7,19,22].
In addition, timely intervention is not always possible
because overdose often occurs in a non-hospital setting
[23]. In a review of medical examiner data, more than
half of the individuals who died from accidental drug
overdoses had already expired before they reached the
emergency department [24].
Naltrexone, a competitive, selective μ-opioid receptor
antagonist, is available in oral and injectable formula-
tions for treatment of alcohol dependence and blockade
of opioid effects [25-27]. Although it is not currently
indicated for reversal of opioid-induced respiratory
depression, naltrexone may provide an early intervention
option to reduce deaths from opioid-induced respiratory
depression.
Naltrexone is a component of morphine sulfate and nal-
trexone hydrochloride extended release capsules (MS-
sNT, EMBEDA
® ), indicated for moderate-to-severe pain
when a continuous, around-the-clock opioid analgesic is
needed for an extended period of time. The formulation
contains pellets of extended release morphine, each with a
sequestered core of naltrexone hydrochloride at a fixed
25:1 ratio of morphine sulfate:naltrexone hydrochloride
(4% naltrexone) [28,29]. Taken as directed, morphine pro-
vides analgesia while the naltrexone remains sequestered
[29-32]. The product is designed so that tampering by
crushing will rapidly release morphine and naltrexone.
The released naltrexone is available to reduce morphine-
induced effects, such as euphoria [28,29]. The quantity of
naltrexone sequestered in MS-sNT (e.g., 4% of the mor-
phine dose or 1.2 mg of naltrexone in a capsule containing
30 mg of morphine) is substantially lower than that used
clinically (50 mg once daily oral dose) for blockade of
opioid effects or alcohol dependence or that which yields
90% occupancy of human opiate receptors (32-48 mg total
daily oral dose) [26,28,33]. Results of an earlier study in
non-dependent opioid-experienced volunteers have shown
that the naltrexone in crushed MS-sNT taken orally was
successful in mitigating morphine-induced subjective
effects, such as drug liking and euphoria [29]. Similarly,
this study in non-dependent recreational opioid users was
designed to simulate IV injection of tampered MS-sNT
and was conducted by injecting morphine sulfate (30 mg)
and naltrexone hydrochloride (1.2 mg) in the same 25:1
ratio in the MS-sNT formulation. When both morphine
and naltrexone were administered intravenously, naltrex-
one reduced morphine-induced euphoric effects [34]. This
study also included measurements of end-tidal carbon
dioxide (EtCO2) concentrations using noninvasive capno-
graphy as an exploratory end point. As EtCO2 monitoring
in the operating room is standard practice for evaluating
ventilation [35], it may be considered a surrogate end
point of respiratory depression [36]. The EtCO2 measure-
m e n t sf r o mt h i sI Vm o r p h i n ea n dn a l t r e x o n es t u d y[ 3 4 ]
are presented here to consider whether the naltrexone
within MS-sNT could attenuate respiratory depression in
opioid overdose if MS-sNT were crushed and taken
intravenously.
Methods
Study design
The study was a single-center, placebo-controlled, rando-
mized, double-blind, 3-way crossover study [34]. The pri-
mary objective of the study was to determine drug liking
and euphoric effects of IV morphine alone and IV mor-
phine + IV naltrexone. These data were published pre-
viously [34]. Evaluation of effects on respiratory depression
as measured by EtCO2 was a secondary, exploratory objec-
tive of the study [34] and these data are reported here. The
study was conducted in accordance with current US Food
and Drug Administration regulations, International
Conference on Harmonisation Guidelines, Good Clinical
Practice standards, Declaration of Helsinki, and local ethi-
cal and legal requirements. Subjects signed an informed
consent form approved by an institutional review board
(Compass IRB, Mesa, AZ) before participation in the study
[34,37,38].
Subjects
Subjects were enrolled if they were male between the
ages of 18 and 50 years and were opioid-preferring,
non-opioid-dependent, recreational drug users who
reported inappropriately taking a prescription opioid to
achieve a high at least 5 times within the previous 12
months [34]. Subjects were to be in generally good
health as determined by medical history and physical
examination. Subjects with a history of significant pul-
monary, neurological, hepatic, renal, endocrine, cardio-
vascular, gastrointestinal, or metabolic disease were
excluded [34].
Interventions
Investigators determined whether subjects were opioid-
dependent by administration of an IV challenge of
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Page 2 of 70.4 mg naloxone [34]. Subjects identified as non-depen-
dent were randomized to receive either 10 mg morphine
or placebo IV separated by a 1-day washout to deter-
mine ability to discriminate morphine from placebo
based on responses to the Drug Effects Questionnaire
(DEQ), and the Cole/Addiction Research Center Inven-
tory (ARCI) Stimulation-Euphoria modified scale [34,39].
All subjects who were able to discriminate morphine
from placebo entered the double-blind treatment phase
during which subjects received each of three study treat-
ments in a random order (separated by a 6-day outpati-
ent washout period): 1) as i n g l e3 0m gI Vb o l u so f
m o r p h i n ei m m e d i a t e l yf o l l o w e db yas i n g l eI Vb o l u so f
naltrexone placebo; 2) a single 30 mg IV bolus of mor-
phine immediately followed by a single 1.2 mg IV bolus
of naltrexone; or 3) a single IV bolus of morphine pla-
cebo immediately followed by a single IV bolus of nal-
trexone placebo. Each IV administration was spaced < 30
seconds apart [34]. The subjects were required to have a
negative screen for drugs and alcohol on readmission for
each treatment period.
EtCO2 measures
Assessments were made immediately before dosing (t = 0)
and immediately following pharmacokinetic sampling at 5,
15, 30, 45, 60, 120, 150, 180, 210, 240, 270, 300, 360, 480,
720, and 1440 minutes post-dose. EtCO2 was measured in
millimeters of mercury (mm Hg) using noninvasive capno-
graphy [40]. A CAPNOGARD
® EtCO2 monitoring system
(Novametrix Medical Systems, Inc., Wallingford, CT,
USA) was used with an airway adapter and subject mouth-
piece. Subjects were instructed to breathe normally
through the mouthpiece for 1 minute. For each respiratory
assessment, maximum effect (Emax), time to maximum
effect (TEmax), and area under the effect curve computed
using the linear trapezoidal rule (AUE, from time 0 to 2, 8,
and 24 hours post-dose [AUE0-2,A U E 0-8,a n dA U E 0-24])
were summarized. Clinical significance was not assessed in
this study.
Statistics
A linear mixed model (PROC Mixed SAS
® ), with fixed
effects for sequence, period, and treatment and a ran-
dom effect for subject nested in sequence, was used to
compare EtCO2 measures among treatments [34]. Least
squares (LS) means and 95% confidence intervals (CIs)
were determined for each treatment as well as the LS
mean differences and 95% CIs for each treatment com-
parison. For Emax,A U E 0-2,A U E 0-8 and AUE 0-24,p a i r -
wise comparisons of each treatment were performed.
Analysis populations were:
￿ Safety population: all subjects who received at least 1
dose of study drug during the double-blind treatment
phase.
￿ PD population: all subjects who received at least 1
dose of study drug during the double-blind treatment
phase and provided at least 1 PD assessment during the
double-blind treatment phase.
￿ Evaluable PD population: all subjects in the PD
population who completed the morphine + naltrexone
treatment and at least 1 other study treatment during
the double-blind treatment phase.
Results
Of the 28 male subjects in the Safety population who
received at least 1 dose of study drug, 2 discontinued;
1 for noncompliance and 1 because of a tooth infection.
All 28 subjects were included in the PD population. Sub-
jects in the Safety population had a mean age of 23.8
years (range, 18-36 years) and 89% were white. All sub-
jects had a history of recreational drug abuse as a criter-
ion of study entry and many were current smokers
(nicotine) and regularly consumed alcohol. Of the 2 sub-
jects who discontinued, 1 did so during placebo treat-
ment and prior to the morphine + naltrexone treatment
(i.e., only completed morphine), the other during mor-
phine treatment and prior to placebo (i.e., only com-
pleted morphine + naltrexone). The Evaluable PD
population, therefore, included 27 subjects for morphine,
27 for morphine + naltrexone, and 26 for placebo.
Primary and secondary outcomes have been reported
previously [34] and are briefly summarized here. Mor-
phine + naltrexone significantly reduced mean pharma-
codynamic assessments of high, euphoria and drug
liking compared with morphine alone, although both
active treatments were significantly higher than placebo
[34]. Mean pupil diameter was significantly reduced
with morphine compared with placebo and morphine +
naltrexone [34].
Mean EtCO2 values over time are illustrated in Figure 1.
Morphine administered alone increased mean EtCO2 vs
placebo over the entire 24-hour post-dose period, with
increases apparent as early as 5 minutes post-dose. The
EtCO2 profile over time for morphine + naltrexone
remained significantly below that of morphine alone for
approximately 6 hours, and numerically lower through
12 hours (Figure 1). The increase from pre-dose EtCO2
values to Emax for morphine + naltrexone (mean, 6.6 mm
Hg; median, 6.0 mm Hg) and placebo (mean, 5.3 mm Hg;
median 5.0 mm Hg) were smaller than for morphine alone
(mean, 10.4 mm Hg; median, 9.0 mm Hg) (Figure 2).
Individual EtCO2 values ranged from 20 to 46 mm Hg
prior to dosing. During the double-blind treatment phase,
individual EtCO2 Emax values ranged from 39 to 61 mm
Hg for morphine alone; 38 to 49 mm Hg for morphine +
naltrexone; and 37 to 49 mm Hg for placebo. Individual
EtCO2 values for the morphine + naltrexone treatment
never exceeded the maximum value for placebo. The
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for all 3 treatments was similar (morphine, 5.0 to 21.0 mm
Hg; morphine + naltrexone, 1.0 to 15.0 mm Hg; placebo,
0.0 to 19.0 mm Hg).
In the Evaluable PD population, statistically significant
differences were observed for EtCO2 LS means across all
treatments for Emax,A U E 0-2, and AUE0-8 (all p < 0.0001)
and AUE0-24 (p = 0.0011) (Table 1). Treatment comparison
for EtCO2 Emax indicated that for morphine + naltrexone,
Emax was significantly reduced vs Emax for IV morphine
alone (p < 0.0001), while the Emax values for morphine +
naltrexone vs placebo were not significantly different (p =
0.3064). There was no difference between morphine + nal-
trexone and morphine alone in EtCO2 AUE0-24 (p =
0.3256). Median TEmax was delayed for morphine + nal-
trexone vs morphine alone (5.0 hours vs 1.0 hour) and pla-
cebo (2.0 hours). The mean respiratory rates showed a
slight suppression for the morphine group at all time
Figure 1 Mean EtCO2 (mm Hg) ± SEM over 24 hours post-dose (PD population).
Figure 2 Mean pre-dose EtCO2 and post-dose Emax EtCO2 (mm Hg)(PD population). Error bars represent SEMs.
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dose 1.71/min) but no group showed a mean lower than
16/min.
Discussion
With the increase in opioid-related drug overdose deaths
in the United States comes a need for harm reduction
strategies not only to address the issues of misuse, abuse,
and diversion at their sources, but also to consider what
might occur in the community setting. The naltrexone
contained in MS-sNT was designed for release if there is
tampering, to mitigate the psychogenic effects of mor-
phine, such as drug liking, high, and euphoria. The cur-
rent analysis reports results of an exploratory outcome
(which was part of the Webster et al. study [34]), which
assessed the impact of naltrexone on EtCO2, a surrogate
measure of respiratory depression, when naltrexone was
coadministered intravenously with morphine in the ratio
(4%) present in the MS-sNT formulation. It was intended
as a clinical simulation of the effects if MS-sNT were to
be completely crushed, solubilized, and injected by non-
dependent, recreational opioid users.
In this study, no subject receiving any treatment was
reported by the investigator to have clinically relevant
respiratory depression at the IV morphine dose adminis-
tered (30 mg). However, compared with placebo, mor-
phine alone resulted in immediate increases in EtCO2
that were maintained for 24 hours post-dose. Morphine
+ naltrexone (25:1 ratio) significantly reduced maximum
EtCO2 vs morphine alone. No significant difference was
detected between the combination morphine + naltrex-
one and placebo in EtCO2 levels at Emax, emphasizing the
PD effect of morphine displacement from the μ-opioid
receptor by naltrexone.
There is no consensus on which measures define clini-
cally relevant respiratory depression, since it can vary by
patient depending on factors such as their condition,
position, sleep state, etc. For this study, EtCO2 at Emax
was considered a sensitive early measure of respiratory
depression because it is an expression of the acute effect
of the opioid at the moment. A rising EtCO2 can reflect
hypoventilation, which may precede other signs of
respiratory depression such as hypoxia [36]. Although
there is no consensus on measures that define clinically
relevant respiratory depression, an EtCO2 >5 0m mH g
has been used as a criterion for respiratory depression in
clinical trials during procedural sedation [36,41,42]. In
the current trial, the highest individual levels measured
with the morphine + naltrexone and the placebo treat-
ments were 49 mm Hg. A retrospective review of the
data indicates that there were 4 subjects who had values
> 50 mm Hg, all with the morphine treatment. The high-
est individual level with the morphine treatment was 61
mm Hg. A change in EtCO2 of ≥ 10 mm Hg had been
suggested as an additional indicator of respiratory
depression in patients under sedation [36]. Three sub-
jects in the placebo arm, 6 in the morphine + naltrexone
arm, and 13 in the morphine arm (including 3 of the 4
subjects with EtCO2 ≥ 50 mm Hg), had changes ≥ 10
mm Hg. As subjects in this study were awake rather than
sedated, the clinical relevance of these changes is
unknown, although the changes of increasing EtCO2 may
indicate early respiratory suppression.
Results of the study reported here for EtCO2 are similar
to those reported by Stoops et al [7], in which physiologi-
cal measures for morphine (arterial oxygen saturation
and pupil diameter) were apparent within 5 minutes of
IV drug administration (5, 10, and 20 mg morphine
doses) and were maintained for approximately 6 hours
following opioid dosing [7]. The subjective psychody-
namic effects of IV administration of opioids are also
apparent early, within 10 minutes, of opioid dosing, but
begin to decrease within 30 minutes after dosing [7,34].
The observation that the physiological effects (EtCO2,
oxygen saturation and pupil diameter) last much longer
than the subjective effects has clinical relevance. Indivi-
duals who abuse opioids may be unaware of the continu-
ing physiological effects of the first opioid dose and the
potential for compounding effects on respiratory depres-
sion by injecting additional opioid, and may re-inject
Table 1 Summary assessment of EtCO2 (Evaluable PD Population)
Parameter* Morphine
N=2 7
Morphine + Naltrexone
N=2 7
Placebo
N=2 6
TEmax,h ,
median (range)
1.0 (0.3, 8.0) 5.0 (0.1, 12.0) 2.0 (0.0, 24.0)
Emax, mm Hg 47.1 (45.7, 48.5)
a 42.9 (41.5, 44.3)
b 41.9 (40.5, 43.3)
AUE0-2 (h￿mm Hg) 11.1 (8.8, 13.5)
a 4.8 (2.4, 7.1)
a,b 1.6 (-0.8, 4.0)
AUE0-8 (h￿mm Hg) 42.7 (33.0, 52.3)
a 21.1 (11.5, 30.8)
a,b 4.6 (-5.2, 14.5)
AUE0-24 (h￿mm Hg) 96.3 (63.3, 129.3)
a 74.6 (41.6, 107.6)
a 11.8 (-21.9, 45.4)
*Except for TE max all values are LS means (95% CI); TE max is median (range)
Comparisons vs placebo:
ap < 0.05
Comparisons vs morphine:
bp < 0.05
AUE = area under the effect curve; CI = confidence interval; Emax = maximum effect; LS = least squares; NS = not significant; TEmax = time to maximum effect
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This also illustrates that μ-opioid receptor PD effects
have different rates of onset, duration of effects, and
slopes of dissipation. The effect of naltrexone coadminis-
tered with morphine on reduction of EtCO2 values vs
morphine alone was evident as early as 5 minutes and
continued through 8 hours when the difference dimin-
ished (Figure 1). The prolonged action of morphine was
longer than the effect of the naltrexone blockage, as the
mean EtCO2 values were similar between morphine +
naltrexone compared with morphine alone at 12 hours
(see Figure 1). This suggests that additional dosing of
antagonist may be needed if a patient were to have clini-
cally significant morphine-induced respiratory
depression.
Results of this exploratory outcome are limited to 1
surrogate measure of respiratory function, using a set
dose of morphine/naltrexone, at designated time frames,
in a small, male population in a specific setting. The
effects of naltrexone alone were also not evaluated in this
study. Clinical significance was not assessed in this study,
although no subjects were reported by the investigator to
show signs of clinically relevant respiratory depression.
In addition, this study was a clinical simulation of IV
administration of tampered (fully crushed) MS-sNT,
rather than administration of actual tampered product,
due to concern about potential injury to the cardiopul-
monary system from injection of excipients such as talc
and particulate matter that may be present in crushed
MS-sNT. This further limits the extrapolation to effects
on EtCO2 of abuse by injection of actual crushed MS-
sNT. Future studies using an array of validated and sensi-
tive measures of respiratory depression, at opioid doses
relevant for respiratory depression, would be needed to
demonstrate consistent changes in these parameters and
to document effects on clearly defined respiratory func-
tion. Assessments to accurately measure the early onset
of opioid-induced respiratory depression and withdrawal
would provide valuable clinically meaningful information.
However, while these assessments can be performed
under research conditions in a clinical setting, it is
important to recognize that overdoses often occur in the
community setting with many confounding factors and
without access to measurement tools.
Conclusions
Results of this exploratory analysis demonstrate signifi-
cant reduction in EtCO2 after IV morphine + naltrexone
vs morphine alone. Further, EtCO2 levels were not sig-
nificantly different between morphine + naltrexone and
placebo, emphasizing the PD effect of naltrexone displa-
cement of morphine from the μ-opioid receptor. This is
t h ef i r s ti n d i c a t i o nt h a ta b u s eo fM S - s N Tb yc r u s h i n g
and injection may not only abate morphine-induced
drug liking and euphoria but may also attenuate mor-
phine-induced effects on EtCO2.F u r t h e rs t u d i e su s i n g
an array of sensitive measures of respiratory depression
to determine the impact of coadministration of mor-
phine sulfate and naltrexone hydrochloride in the 25:1
ratio present in MS-sNT on measures of respiratory
depression may increase understanding of the harm
reduction potential of MS-sNT.
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